TABLE OF CONTENTS
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE SCLERODERMA THERAPEUTICS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 EUROPE SCLERODERMA THERAPEUTICS MARKET : GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7 DBMR MARKET POSITION GRID
2.8 TIME LINE
2.9 MULTIVARIATE MODELLING
2.10 SECONDARY SOURCES
2.11 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.1.1 RISING CASES OF SCLERODERMA
3.1.2 INCREASING ACCESS TO MEDICAL INSURANCE IN THE U.S.
3.1.3 INCREASING MERGER AND ACQUISITIONS
3.2 RESTRAINTS
3.2.1 LACK OF CURATIVE TREATMENT
3.2.2 STRINGENT REGULATIONS
3.2.3 COUNTERFEIT PRODUCTS
3.3 OPPORTUNITY
3.3.1 UNMET PATIENT NEEDS IN SYSTEMIC SCLEROSIS
3.4 CHALLENGE
3.4.1 SIDE EFFECTS OF DRUGS
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
6 PIPELINE PRODUCTS
7 EPIDEMIOLOGY
7.1 HISTORY OF SCLERODERMA:
7.2 RECENT INCIDENCE AND PREVALENCE:
7.3 CAUSE OF SCLERODERMA:
7.4 SYMPTOMS OF SCLERODERMA:
7.5 MANAGING SCLERODERMA:
8 EUROPE SCLERODERMA THERAPEUTICS MARKET, BY TYPE
8.1 OVERVIEW
8.2 SYSTEMIC SCLERODERMA
8.2.1 LIMITED CUTANEOUS SYSTEMIC SCLEROSIS OR CREST SYNDROME
8.2.2 DIFFUSE SYSTEMIC SCLEROSIS
8.3 LOCALIZED SCLERODERMA
8.3.1 MORPHEA
8.3.2 LINEAR SCLERODERMA
9 EUROPE SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE
9.1 OVERVIEW
9.2 DRUG TREATMENT
9.2.1 DRUG TREATMENT, BY TYPE
9.2.1.1 ANTI-INFLAMMATORY DRUGS
9.2.1.2 IMMUNOSUPPRESSANTS
9.2.1.3 CORTICOSTEROIDS
9.2.1.4 PROTON PUMP INHIBITORS
9.2.1.5 CALCIUM CHANNEL BLOCKERS
9.2.1.6 ACE INHIBITORS
9.2.1.7 H2 BLOCKERS
9.2.1.8 PDE5 INHIBITORS
9.2.1.9 PROSTACYCLIN ANALOGUES
9.2.1.10 ENDOTHELIN RECEPTOR ANTAGONISTS
9.2.1.11 CHELATING AGENTS (EDATHAMIL DISODIUM)
9.2.1.12 OTHERS
9.2.2 DRUG TREATMENT, BY DISTRIBUTION CHANNEL
9.2.2.1 HOSPITAL PHARMACY
9.2.2.2 RETAIL PHARMACY
9.2.2.3 ONLINE PHARMACY
9.2.2.4 OTHERS
9.3 SURGICAL TREATMENT
?
9.4 THERAPY
9.4.1 ULTRAVIOLET LIGHT THERAPY
9.4.2 PHYSICAL THERAPY
9.4.3 OTHERS
10 EUROPE SCLERODERMA THERAPEUTICS MARKET, BY END USER
10.1 OVERVIEW
10.2 HOSPITAL
10.3 SPECIALTY CLINICS
10.4 HOMECARE SETTINGS
10.5 OTHERS
11 EUROPE SCLERODERMA THERAPEUTICS MARKET, BY GEOGRAPHY
11.1 EUROPE
11.1.1 U.K.
11.1.2 GERMANY
11.1.3 FRANCE
11.1.4 SPAIN
11.1.5 ITALY
11.1.6 NETHERLANDS
11.1.7 SWITZERLAND
11.1.8 BELGIUM
11.1.9 TURKEY
11.1.10 RUSSIA
11.1.11 REST OF EUROPE
12 EUROPE SCLERODERMA THERAPEUTICS MARKET, COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: EUROPE
13 COMPANY PROFILES
13.1 ASTRAZENECA
13.1.1 COMPANY SNAPSHOT
13.1.2 REVENUE ANALYSIS
13.1.3 GEOGRAPHICAL PRESENCE
13.1.4 PRODUCT PORTFOLIO (PIPELINE)
13.1.5 RECENT DEVELOPMENTS
13.2 F. HOFFMANN-LA ROCHE LTD
13.2.1 COMPANY SNAPSHOT
13.2.2 REVENEUE ANALYSIS
13.2.3 GEOGRAPHICAL PRESENCE
13.2.4 PRODUCT PORTFOLIO
13.2.5 RECENT DEVELOPMENTS
13.3 NOVARTIS AG
13.3.1 COMPANY SNAPSHOT
13.3.2 REVENEUE ANALYSIS
13.3.3 GEOGRAPHICAL PRESENCE
13.3.4 PRODUCT PORTFOLIO
13.3.5 RECENT DEVELOPMENTS
13.4 PFIZER INC.
13.4.1 COMPANY SNAPSHOT
13.4.2 REVENEUE ANALYSIS
13.4.3 GEOGRAPHICAL PRESENCE
13.4.4 PRODUCT PORTFOLIO
13.4.5 RECENT DEVELOPMENTS
13.5 ABBVIE INC.
13.5.1 COMPANY SNAPSHOT
13.5.2 REVENEUE ANALYSIS
13.5.3 GEOGRAPHICAL PRESENCE
13.5.4 PRODUCT PORTFOLIO
13.5.5 RECENT DEVELOPMENTS
13.6 ACTIVE BIOTECH AB.
13.6.1 COMPANY OVERVIEW
13.6.2 REVENUE ANALYSIS
13.6.3 PRODUCT PORTFOLIO
13.6.4 RECENT DEVELOPMENT
13.7 ALLERGAN
13.7.1 COMPANY SNAPSHOT
13.7.2 REVENEUE ANALYSIS
13.7.3 GEOGRAPHICAL PRESENCE
13.7.4 PRODUCT PORTFOLIO
13.7.5 RECENT DEVELOPMENTS
13.8 ARGENTIS PHARMACEUTICALS, LLC.
13.8.1 COMPANY OVERVIEW
13.8.2 PRODUCT PORTFOLIO
13.8.3 RECENT DEVELOPMENTS
13.9 BRISTOL-MYERS SQUIBB COMPANY
13.9.1 COMPANY OVERVIEW
13.9.2 REVENUE ANALYSIS
13.9.3 GEOGRAPHICAL PRESENCE
13.9.4 PRODUCTS PORTFOLIO
13.9.5 RECENT DEVELOPMENTS
?
13.10 DAVAL INTERNATIONAL LIMITED
13.10.1 COMPANY SNAPSHOT
13.10.2 GEOGRAPHICAL PRESENCE
13.10.3 PRODUCT PORTFOLIO
13.10.4 RECENT DEVELOPMENT
13.11 GLAXOSMITHKLINE PLC.
13.11.1 COMPANY OVERVIEW
13.11.2 REVENUE ANALYSIS
13.11.3 GEOGRAPHICAL PRESENCE
13.11.4 PRODUCTS PORTFOLIO (PIPELINE DEVELOPMENT)
13.11.5 RECENT DEVELOPMENT
13.12 JOHNSON & JOHNSON SERVICES, INC.
13.12.1 COMPANY OVERVIEW
13.12.2 REVENUE ANALYSIS
13.12.3 GEOGRAPHICAL PRESENCE
13.12.4 PRODUCT PORTFOLIO (PIPELINE)
13.12.5 RECENT DEVELOPMENTS
13.13 SANOFI
13.13.1 COMPANY SNAPSHOT
13.13.2 REVENEUE ANALYSIS
13.13.3 GEOGRAPHICAL PRESENCE
13.13.4 PRODUCT PORTFOLIO
13.13.5 RECENT DEVELOPMENT
13.14 VIDA THERAPEUTICS INC.
13.14.1 COMPANY OVERVIEW
13.14.2 PRODUCT PORTFOLIO
13.14.3 RECENT DEVELOPMENTS
14 QUESTIONNAIRE
15 RELATED REPORTS